MX2020003185A - Nuevos compuestos heterociclicos. - Google Patents

Nuevos compuestos heterociclicos.

Info

Publication number
MX2020003185A
MX2020003185A MX2020003185A MX2020003185A MX2020003185A MX 2020003185 A MX2020003185 A MX 2020003185A MX 2020003185 A MX2020003185 A MX 2020003185A MX 2020003185 A MX2020003185 A MX 2020003185A MX 2020003185 A MX2020003185 A MX 2020003185A
Authority
MX
Mexico
Prior art keywords
modulators
heterocyclic compounds
mglur7
novel heterocyclic
metabotropic glutamate
Prior art date
Application number
MX2020003185A
Other languages
English (en)
Inventor
Guillaume Duvey
Sylvain Celanire
Original Assignee
Pragma Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pragma Therapeutics filed Critical Pragma Therapeutics
Publication of MX2020003185A publication Critical patent/MX2020003185A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención se refiere a nuevos compuestos heterocíclicos. La invención también se refiere a compuestos que son moduladores de los receptores metabotrópicos de glutamato (mGluR), preferentemente del receptor metabotrópico de glutamato subtipo 7 ("mGluR7"). La presente invención también se refiere a una composición farmacéutica que comprenden estos compuestos y su uso para el tratamiento o prevención de trastornos asociados con disfunción de glutamato o en los cuales está implicado el receptor metabotrópico de glutamato, preferentemente el subtipo mGluR7 de receptores metabotrópicos de glutamato.
MX2020003185A 2017-09-26 2018-09-26 Nuevos compuestos heterociclicos. MX2020003185A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17306269.6A EP3459939A1 (en) 2017-09-26 2017-09-26 Novel heterocyclic compounds as modulators of mglur7
PCT/EP2018/076080 WO2019063596A1 (en) 2017-09-26 2018-09-26 NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7

Publications (1)

Publication Number Publication Date
MX2020003185A true MX2020003185A (es) 2020-07-29

Family

ID=60001826

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003185A MX2020003185A (es) 2017-09-26 2018-09-26 Nuevos compuestos heterociclicos.

Country Status (10)

Country Link
US (2) US11414395B2 (es)
EP (2) EP3459939A1 (es)
JP (2) JP2020535208A (es)
CN (1) CN111148744A (es)
AU (1) AU2018340505B2 (es)
CA (1) CA3075954A1 (es)
IL (1) IL273237A (es)
MX (1) MX2020003185A (es)
RU (1) RU2020114432A (es)
WO (1) WO2019063596A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202106871D0 (en) * 2021-05-13 2021-06-30 Addex Pharmaceuticals Sa Novel compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE255894T1 (de) 1998-10-02 2003-12-15 Novartis Pharma Gmbh Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen
WO2005082887A1 (ja) * 2004-02-26 2005-09-09 Aska Pharmaceutical Co., Ltd. ピリミジン誘導体
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006113498A2 (en) * 2005-04-14 2006-10-26 Novartis Vaccines And Diagnostics Inc. 2-amino-quinaz0lin-5-ones as hsp90 inhibitors useful in treating proliferation diseases
EP1917250B1 (en) * 2005-06-27 2010-07-21 Amgen, Inc Anti-inflammatory aryl nitrile compounds
CN101309905A (zh) * 2005-08-12 2008-11-19 阿斯利康(瑞典)有限公司 取代的异吲哚酮及其作为代谢型谷氨酸受体增效剂的用途
WO2007023242A1 (en) * 2005-08-24 2007-03-01 Merz Pharma Gmbh & Co. Kgaa Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors
EP1983993A4 (en) * 2006-02-07 2010-09-22 Merck Sharp & Dohme Niacin receptor agonists, compositions containing such compounds and method of treatment
JP2010506915A (ja) * 2006-10-20 2010-03-04 メルク エンド カムパニー インコーポレーテッド ナイアシン受容体アゴニスト、そのような化合物を含む組成物、及び治療方法
GB0704230D0 (en) * 2007-03-05 2007-04-11 Novartis Ag Organic compounds
EP2150244A1 (en) 2007-04-23 2010-02-10 House Ear Institute Treatment and/or prevention of presbycusis by modulation of metabotropic glutamate receptor 7
US20100298289A1 (en) * 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2017112678A1 (en) * 2015-12-21 2017-06-29 Rima Mcleod Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases

Also Published As

Publication number Publication date
CA3075954A1 (en) 2019-04-04
RU2020114432A3 (es) 2022-01-17
EP3672950A1 (en) 2020-07-01
AU2018340505A1 (en) 2020-03-19
AU2018340505B2 (en) 2024-04-04
JP2023178455A (ja) 2023-12-14
CN111148744A (zh) 2020-05-12
US20220363664A1 (en) 2022-11-17
JP2020535208A (ja) 2020-12-03
US11414395B2 (en) 2022-08-16
US20200231563A1 (en) 2020-07-23
IL273237A (en) 2020-04-30
WO2019063596A1 (en) 2019-04-04
EP3459939A1 (en) 2019-03-27
RU2020114432A (ru) 2021-10-27

Similar Documents

Publication Publication Date Title
MX2011005242A (es) Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos.
MX2020006460A (es) Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
PH12017500161A1 (en) 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
NZ737399A (en) Ccr2 modulators
ZA201907746B (en) 6-5 fused rings as c5a inhibitors
JO3368B1 (ar) مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
PH12017500170A1 (en) 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
MX2023000677A (es) Compuestos moduladores de receptor de estrogeno.
MX2019014292A (es) Anillos 5-5 fusionados como inhibidores c5a.
MX2017001453A (es) Compuestos de 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-ona y su uso como moduladores alostericos negativos de receptores de glutamato metabotropico subtipo 2 (mglur2).
ZA202001321B (en) Indazole compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
NZ734400A (en) Amide compounds as 5-ht4 receptor agonists
MX2018002446A (es) Compuestos heterociclicos fusionados como moduladores s1p.
MX2023005408A (es) Compuestos y su uso en el tratamiento de trastornos mediados por el receptor de taquiquinina.
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
MX2012007005A (es) Tiazoles biciclicos como moduladores alostericos de recptores de glutamato metabotropico subtipo 5.
PH12016500312A1 (en) 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
MX2018014185A (es) Combinacion de antagonistas puros del receptor 5 ht6 con inhibidores de la acetilcolinesterasa.
NZ763341A (en) Polycyclic amides as muscarinic m1 receptor positive allosteric modulators
MX2020003185A (es) Nuevos compuestos heterociclicos.
WO2012061019A3 (en) Tricyclic mglur5 receptor modulators
PH12017501736A1 (en) Indole derivatives
MX2012007006A (es) Tiazoles biciclicos como moduladores alostericos de receptores mglur5.
MX2017010630A (es) Derivado de imidazopirimidina e imidazotriazina, y composicion farmaceutica que lo comprende.
WO2012058128A3 (en) Caprolactam mglur5 receptor modulators